A. Jemal, R. Siegel, J. Xu, and E. Ward, Cancer Statistics, 2010, CA: A Cancer Journal for Clinicians, vol.60, issue.5, pp.277-300, 2010.
DOI : 10.3322/caac.20073

J. Wydra, W. Kruszewski, W. Jasi?ski, M. Szajewski, M. Ciesielski et al., Is Age a??Risk Factor of Postoperative Complications in Colorectal Cancer?, Polish Journal of Surgery, vol.85, issue.9, pp.491-495, 2013.
DOI : 10.2478/pjs-2013-0076

H. Wildiers, I. Kunkler, L. Biganzoli, J. Fracheboud, G. Vlastos et al., Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology, The Lancet Oncology, vol.8, issue.12, pp.1101-1115, 2007.
DOI : 10.1016/S1470-2045(07)70378-9

L. Hutchins, J. Unger, J. Crowley, C. Coltman, . Jr et al., Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials, New England Journal of Medicine, vol.341, issue.27, pp.2061-2067, 1999.
DOI : 10.1056/NEJM199912303412706

J. Lewis, M. Kilgore, D. Goldman, E. Trimble, R. Kaplan et al., Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials, Journal of Clinical Oncology, vol.21, issue.7, pp.1383-1389, 2003.
DOI : 10.1200/JCO.2003.08.010

K. Woodhouse, Pharmacokinetics of drugs in the elderly, J R Soc Med, vol.87, pp.2-4, 1994.

K. Turnheim, When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly, Experimental Gerontology, vol.38, issue.8, pp.843-853, 2003.
DOI : 10.1016/S0531-5565(03)00133-5

C. Twelves, Vision of the Future: Capecitabine, The Oncologist, vol.6, issue.90004, pp.35-39, 2001.
DOI : 10.1634/theoncologist.6-suppl_4-35

M. Miwa, M. Ura, M. Nishida, N. Sawada, T. Ishikawa et al., Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue, European Journal of Cancer, vol.34, issue.8, pp.1274-1281, 1998.
DOI : 10.1016/S0959-8049(98)00058-6

R. Gieschke, H. Burger, B. Reigner, K. Blesch, and J. Steimer, Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients, British Journal of Clinical Pharmacology, vol.16, issue.3, pp.252-263, 2003.
DOI : 10.1046/j.1365-2125.2003.01765.x

I. Judson, P. Beale, J. Trigo, W. Aherne, T. Crompton et al., A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug, Investigational New Drugs, vol.17, issue.1, pp.49-56, 1999.
DOI : 10.1023/A:1006263400888

B. Reigner, K. Blesch, and E. Weidekamm, Clinical Pharmacokinetics of Capecitabine, Clinical Pharmacokinetics, vol.19, issue.12, pp.85-104, 2001.
DOI : 10.2165/00003088-200140020-00002

S. Louie, B. Ely, H. Lenz, K. Albain, C. Gotay et al., Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030), British Journal of Cancer, vol.6, issue.7, pp.1744-1749, 2013.
DOI : 10.1124/dmd.109.028209

R. Gieschke, B. Reigner, K. Blesch, and J. Steimer, Population pharmacokinetic analysis of the major metabolites of capecitabine, Journal of Pharmacokinetics and Pharmacodynamics, vol.29, issue.1, pp.25-47, 2002.
DOI : 10.1023/A:1015716617967

S. Urien, K. Rezaí, and F. Lokiec, Pharmacokinetic Modelling of 5-FU Production from Capecitabine???A Population Study in 40 Adult Patients with Metastatic Cancer, Journal of Pharmacokinetics and Pharmacodynamics, vol.52, issue.5-6, pp.817-833, 2005.
DOI : 10.1007/s10928-005-0018-2

C. Grande, G. Quintero, S. Candamio, P. Bouzas, L. Villanueva et al., Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer, Journal of Geriatric Oncology, vol.4, issue.2, pp.114-121, 2013.
DOI : 10.1016/j.jgo.2013.01.001

D. Cunningham, I. Lang, E. Marcuello, V. Lorusso, J. Ocvirk et al., Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial, The Lancet Oncology, vol.14, issue.11, pp.1077-1085, 2013.
DOI : 10.1016/S1470-2045(13)70154-2

R. Freedman, B. Pitcher, N. Keating, K. Ballman, J. Mandelblatt et al., Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907, Breast Cancer Research and Treatment, vol.14, issue.1, pp.607-616, 2013.
DOI : 10.1007/s10549-013-2562-6

G. Milano, PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression, Clin Pharmacol, vol.83, pp.829-839, 2008.

S. Beal, L. Sheiner, A. Boeckmann, and R. Bauer, NONMEM User's Guide; NONMEM project group, University of California Prediction of creatinine clearance from serum creatinine, pp.31-41, 1976.

M. Etienne, E. Chatelut, X. Pivot, M. Lavit, A. Pujol et al., Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis, European Journal of Cancer, vol.34, issue.1, pp.92-97, 1998.
DOI : 10.1016/S0959-8049(97)00345-6

J. Parke, N. Holford, and B. Charles, A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models, Computer Methods and Programs in Biomedicine, vol.59, issue.1, pp.19-29, 1999.
DOI : 10.1016/S0169-2607(98)00098-4

C. Terret, E. Erdociain, R. Guimbaud, M. Boisdron-celle, H. Mcleod et al., Dose and time dependencies of 5-fluorouracil pharmacokinetics, Clinical Pharmacology & Therapeutics, vol.68, issue.3, pp.270-279, 2000.
DOI : 10.1067/mcp.2000.109352

R. Fety, F. Rolland, M. Barberi-heyob, A. Hardoin, L. Campion et al., Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinoma, Clin Cancer Res, vol.4, pp.2039-2045, 1998.

C. Poole, J. Gardiner, C. Twelves, P. Johnston, P. Harper et al., Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients, Cancer Chemotherapy and Pharmacology, vol.49, issue.3, pp.225-234, 2002.
DOI : 10.1007/s00280-001-0408-0

J. Blum, S. Jones, A. Buzdar, P. Lorusso, I. Kuter et al., Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer, Journal of Clinical Oncology, vol.17, issue.2, pp.485-493, 1999.
DOI : 10.1200/JCO.1999.17.2.485

S. Abushullaih, E. Saad, M. Munsell, and P. Hoff, Incidence and severity of handfoot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience, Cancer, vol.20, pp.3-10, 2002.

I. Kara, B. Sahin, and M. Erkisi, Palmar???plantar erythrodysesthesia due to docetaxel???capecitabine therapy is treated with vitamin E without dose reduction, The Breast, vol.15, issue.3, pp.414-424, 2006.
DOI : 10.1016/j.breast.2005.07.007

R. Bruno, D. Hille, A. Riva, N. Vivier, W. Bokkelhuinnink et al., Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer., Journal of Clinical Oncology, vol.16, issue.1, pp.187-196, 1998.
DOI : 10.1200/JCO.1998.16.1.187